Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
Targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging and restaging at biochemical recurrence in patients with PCa, where...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/5/1169 |
| _version_ | 1797475536773054464 |
|---|---|
| author | Wietske I. Luining Matthijs C. F. Cysouw Dennie Meijer N. Harry Hendrikse Ronald Boellaard André N. Vis Daniela E. Oprea-Lager |
| author_facet | Wietske I. Luining Matthijs C. F. Cysouw Dennie Meijer N. Harry Hendrikse Ronald Boellaard André N. Vis Daniela E. Oprea-Lager |
| author_sort | Wietske I. Luining |
| collection | DOAJ |
| description | Targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging and restaging at biochemical recurrence in patients with PCa, where it has shown superior detection rates compared to previous imaging modalities. Apart from targeting PSMA for diagnostic purposes, there is a growing interest in developing ligands to target the PSMA-protein for radioligand therapy (RLT). PSMA-based RLT is a novel treatment that couples a PSMA-antibody to (alpha or beta-emitting) radionuclide, such as Lutetium-177 (<sup>177</sup>Lu), to deliver high radiation doses to tumor cells locally. Treatment with <sup>177</sup>Lu-PSMA RLT has demonstrated a superior overall survival rate within randomized clinical trials as compared to routine clinical care in patients with metastatic castration-resistant prostate cancer (mCRPC). The current review provides an overview of the literature regarding recent developments in nuclear medicine related to PSMA-targeted PET imaging and Theranostics. |
| first_indexed | 2024-03-09T20:45:31Z |
| format | Article |
| id | doaj.art-41ce6ac70b9941708400579ccdbcea7e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:45:31Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-41ce6ac70b9941708400579ccdbcea7e2023-11-23T22:46:57ZengMDPI AGCancers2072-66942022-02-01145116910.3390/cancers14051169Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate CancerWietske I. Luining0Matthijs C. F. Cysouw1Dennie Meijer2N. Harry Hendrikse3Ronald Boellaard4André N. Vis5Daniela E. Oprea-Lager6Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Location VUmc, 1081 HV Amsterdam, The NetherlandsDepartment of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Location VUmc, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Location VUmc, 1081 HV Amsterdam, The NetherlandsDepartment of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The NetherlandsDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Location VUmc, 1081 HV Amsterdam, The NetherlandsTargeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging and restaging at biochemical recurrence in patients with PCa, where it has shown superior detection rates compared to previous imaging modalities. Apart from targeting PSMA for diagnostic purposes, there is a growing interest in developing ligands to target the PSMA-protein for radioligand therapy (RLT). PSMA-based RLT is a novel treatment that couples a PSMA-antibody to (alpha or beta-emitting) radionuclide, such as Lutetium-177 (<sup>177</sup>Lu), to deliver high radiation doses to tumor cells locally. Treatment with <sup>177</sup>Lu-PSMA RLT has demonstrated a superior overall survival rate within randomized clinical trials as compared to routine clinical care in patients with metastatic castration-resistant prostate cancer (mCRPC). The current review provides an overview of the literature regarding recent developments in nuclear medicine related to PSMA-targeted PET imaging and Theranostics.https://www.mdpi.com/2072-6694/14/5/1169prostate cancerprostate-specific membrane antigenPET/CTTheranostics |
| spellingShingle | Wietske I. Luining Matthijs C. F. Cysouw Dennie Meijer N. Harry Hendrikse Ronald Boellaard André N. Vis Daniela E. Oprea-Lager Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer Cancers prostate cancer prostate-specific membrane antigen PET/CT Theranostics |
| title | Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer |
| title_full | Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer |
| title_fullStr | Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer |
| title_full_unstemmed | Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer |
| title_short | Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer |
| title_sort | targeting psma revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer |
| topic | prostate cancer prostate-specific membrane antigen PET/CT Theranostics |
| url | https://www.mdpi.com/2072-6694/14/5/1169 |
| work_keys_str_mv | AT wietskeiluining targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT matthijscfcysouw targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT denniemeijer targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT nharryhendrikse targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT ronaldboellaard targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT andrenvis targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer AT danielaeoprealager targetingpsmarevolutionizestheroleofnuclearmedicineindiagnosisandtreatmentofprostatecancer |